Orion Engineered Carbons S.A. (NYSE:OEC), a worldwide supplier of
specialty and high-performance Carbon Black, today announced that its
board of directors has declared an interim dividend of €0.67 *
per common share, equivalent to a total distribution of €40 million.
THE HAGUE , January 29, 2015 /PRNewswire/ -- The Board of Royal Dutch Shell plc ("RDS") (NYSE:RDS.A) (NYSE:RDS.B) today announced an interim dividend in respect of the fourth quarter of 2014 of US$0.47 per A ordinary share ("A Share") and B ordinary share ("B Share"), an increase of US$0.02 on the equivalent US dollar dividend for the same quarter last year.
Sign-up for Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its Human Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease Presented at the American Society of Hematology Annual Meeting investment picks
Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a
biopharmaceutical company developing PRX302 (topsalysin) for the
treatment of symptoms of benign prostatic hyperplasia (BPH, enlarged
prostate) and the treatment of localized prostate cancer, today
announced findings from an administrative interim analysis of efficacy
in its ongoing Phase 3 “PLUS-1” trial of PRX302 as a treatment for lower
urinary tract symptoms of BPH.
MGE Energy, Inc. (Nasdaq: MGEE) today published its investor newsletter
"Interim Report" with the following topics:
- Rate changes - Third-quarter earnings reported - Investor
tax information - Lobbying reports available online - Natural
The newsletter is available on MGE Energy's website at:
Interim Report is published quarterly to provide investors with
information about MGE Energy and its primary subsidiary, Madison Gas and
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced that interim results from an
ongoing Phase II clinical trial of Puma's investigational drug PB272
(neratinib) were presented at the 2014 CTRC-AACR San Antonio Breast
Cancer Symposium (SABCS) that is currently taking place in San Antonio,
Aldoxorubicin Shows a Complete Response, Tumor Shrinkage, Prolonged Stable Disease, and Favorable Tolerability in Patients Novel Albumin-Binding Drug Candidate Appears to Allow Doxorubicin to Cross the Tumor's Blood-Brain Barrier in Humans
LOS ANGELES , Jan.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.